{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:09:53Z","timestamp":1787242193091,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>We reported a case of primary central nervous system lymphoma (PCNSL) coexistent with glial fibrillary acidic protein (GFAP) astrocytopathy, and discussed the problems needing attention in the diagnosis and differential diagnosis of GFAP astrocytopathy. Our patient was a 51-year-old female who presented with somnolence for a month, and memory declination for 10 days. Brain magnetic resonance imaging (MRI) demonstrated multiple abnormal enhancement lesions in bilateral basal ganglia and around the third ventricle, as well as transient T2-weighted hyper-intensity lesions at the splenium of the corpus callosum during the course of the disease. The cerebrospinal fluid (CSF) was positive for anti-GFAP antibodies by antigen-transfected HEK293 cell-based assay (indirect immunofluorescence assay). She was initially diagnosed with autoimmune GFAP astrocytopathy. After treatment with corticosteroids for about 2 months, she displayed poor response and even worsened clinical manifestations when the dose of prednisone reduced to 45 mg. Stereotactic brain biopsy was adopted and the diagnosis of large B-cell lymphoma, non-germinal center type was established on pathological examination. The results of brain biopsy also showed perivascular inflammation and CD8+ T cell infiltration, which also accorded with GFAP astrocytopathy. After chemotherapy with rituximab and methotrexate, the patient showed clinical and radiological improvement significantly. Our findings suggest that positivity of GFAP antibody calls for cautious interpretation. Cancer screening appropriate for age, sex, and risk factors is recommended for GFAP antibody-positive patients, especially for patients with atypical clinical and radiologic manifestations.<\/jats:p>","DOI":"10.3389\/fneur.2022.806224","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T03:23:27Z","timestamp":1643340207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Case Report: Need for Caution in the Diagnosis of GFAP Astrocytopathy\u2014A Case of GFAP Astrocytopathy Coexistent With Primary Central Nervous System Lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Jia","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature","volume":"9","author":"Shan","year":"2018","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s13760-020-01361-y","article-title":"Glial fibrillary acidic protein (GFAP)-antibody in children with focal seizures of undetermined cause","volume":"121","author":"Sava\u015f","year":"2021","journal-title":"Acta Neurol Belg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAP\u03b1 IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"626564","DOI":"10.3389\/fped.2020.626564","article-title":"Glial fibrillary acidic protein astrocytopathy in pediatric patients: a retrospective study","volume":"8","author":"Huang","year":"2021","journal-title":"Front Pediatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/jnnp-2017-316583","article-title":"Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients","volume":"89","author":"Iorio","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"577748","DOI":"10.1016\/j.jneuroim.2021.577748","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis","volume":"361","author":"Kimura","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B8","first-page":"169","article-title":"IgG-antibodies to CNS proteins in patients with multiple sclerosis","volume":"2","author":"Kaiser","year":"1997","journal-title":"Eur J Med Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10803-007-0398-9","article-title":"How relevant are GFAP autoantibodies in autism and Tourette Syndrome?","volume":"38","author":"Kirkman","year":"2008","journal-title":"J Autism Dev Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1464-5491.2009.02911.x","article-title":"Autoantibodies to glial fibrillary acid protein and S100beta in diabetic patients","volume":"27","author":"G\u00f3mez-Touri\u00f1o","year":"2010","journal-title":"Diabet Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s13277-013-0770-7","article-title":"Serum GFAP autoantibody as an ELISA-detectable glioma marker","volume":"34","author":"Wei","year":"2013","journal-title":"Tumour Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e92698","DOI":"10.1371\/journal.pone.0092698","article-title":"Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/00207454.2020.1758084","article-title":"Serum glial fibrillary acidic protein (GFAP)-antibody in idiopathic intracranial hypertension","volume":"131","author":"Yetimler","year":"2021","journal-title":"Int J Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/WCO.0000000000000676","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"32","author":"Kunchok","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"autoimmune glial fibrillary acidic protein astrocytopathy a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/practneurol-2017-001863","article-title":"Glial fibrillary acidic protein antibody-positive meningoencephalomyelitis","volume":"18","author":"Zarkali","year":"2018","journal-title":"Pract Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.21203\/rs.3.rs-839718\/v1","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"53","author":"Zhang","year":"2020","journal-title":"Chin J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2169\/internalmedicine.6457-20","article-title":"Self-remitting elevation of adenosine deaminase levels in the cerebrospinal fluid with autoimmune glial fibrillary acidic protein astrocytopathy: a case report and review of the literature","volume":"49","author":"Nakamura","year":"2018","journal-title":"Neuropediatrics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1212\/01.WNL.0000144274.12174.CB","article-title":"Clinically mild encephalitis\/encephalopathy with a reversible splenial lesion","volume":"63","author":"Tada","year":"2004","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1055\/s-0037-1608779","article-title":"Mild Encephalitis\/Encephalopathy with Reversible Splenial Lesion (MERS) due to cytomegalovirus: case report and review of the literature","volume":"49","author":"Feraco","year":"2018","journal-title":"Neuropediatrics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2169\/internalmedicine.6386-20","article-title":"Central nervous system involvement in mantle cell lymphoma presenting magnetic resonance imaging features of mild encephalitis\/encephalopathy with a reversible splenial lesion","volume":"60","author":"Nakamura","year":"2021","journal-title":"Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3606970","DOI":"10.1155\/2018\/3606970","article-title":"Primary CNS lymphomas: challenges in diagnosis and monitoring","volume":"2018","author":"Chiavazza","year":"2018","journal-title":"Biomed Res Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/ene.13531","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study","volume":"25","author":"Long","year":"2018","journal-title":"Eur J Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000488879","article-title":"Brain immunohistopathology in a patient with autoimmune glial fibrillary acidic protein astrocytopathy","volume":"25","author":"Shu","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/cncr.30965","article-title":"Diagnosis and management of primary central nervous system lymphoma","volume":"123","author":"Han","year":"2017","journal-title":"Cancer."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.806224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T03:23:30Z","timestamp":1643340210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.806224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":27,"alternative-id":["10.3389\/fneur.2022.806224"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.806224","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"article-number":"806224"}}